ARCHIVES

Cytogen Corp.’s Imaging Agent ProstaScint Added to NCCN Prostate Cancer Guidelines.

This article is from The Cancer Letter archive.

Vol. 26 No. 13 | March 31, 2000

Download PDF Visit The Full Archive

Related Articles

In Brief: Outstanding Investigator Awards Draw 150 Letters Of Intent; Applications Due July 15

June 15, 1984

NCI Cooperative Group, Cancer Center Trials Listed

May 30, 2008

Dendritic Cell Vaccine Increases PFS in Phase II Clinical Trial

December 27, 2013

In Brief: Salmon To Step Down As Center Director; Becker To Relinquish Positions At MDACC

September 4, 1998

Senate Committee Adds $100 Million for Cancer, Earmarks Extra Positions for NCI, Backs New Construction

September 19, 1975

Dietary Interventions Reduce Breast Cancer Risk In Trials

May 27, 2005